Polyrizon files patent for nasal drug delivery tech
Raanana, Israel - Polyrizon Ltd. (NASDAQ:PLRZ), a biotech firm in the development stage, has filed a divisional patent application in Israel for its Trap & Target (NYSE:TGT) (T&T) platform technology.
Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform
Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the filing of a ...
Polyrizon files divisional patent application with Israel Patent Office
Polyrizon (PLRZ) announced the filing of a divisional patent application with the Israel Patent Office for its Trap & Target platform ...
Biopharmaceutical Drug Delivery Technologies Market Expanding Steadily At 7.75% CAGR To 335.8 Billion USD By 2032
Biopharmaceutical Drug Delivery Technologies Market The global biopharmaceutical drug delivery technologies <a target=_blank href=https: ...
Resyca BV: Resyca Receives Medical Device Regulation Certificate From TÜV SÜD
MDR Certification Strengthens Resyca's Leadership in Soft Mist Drug-Device Combination Products ENSCHEDE, NL / ACCESS Newswire / January 28, 2025 / Resyca BV, a pioneering leader in the development an ...
Medical News Today3d
FDA-approved nasal spray for severe depression can lead to remission
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
Rolling Out4d
Alzheimer’s new nasal spray stops memory loss
Revolutionary nasal spray offers hope by potentially delaying Alzheimer's progression through cutting-edge neurological ...